Targets › PPAT
8 programs from 8 companies in 9 trials: 3 Phase 3, 2 Phase 4, 2 Phase 2, 2 Phase 1; Immunology, Oncology, Cardiovascular; next expected readout Dec 2026.
Catalyzes the formation of phosphoribosylamine from phosphoribosylpyrophosphate (PRPP) and glutamine. (UniProt, Q06203)
Open in Phaseline: the race on PPAT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Children's Hospital of Fudan University | Azathioprine Amidophosphoribosyltransferase inhibitor | PPAT | Phase 4 | Crohn Disease | Dec 2026 |
| Medical University of Warsaw | Azathioprine Amidophosphoribosyltransferase inhibitor | PPAT | Phase 4 | Myocarditis | Sep 2027 |
| Hospices Civils de Lyon | Azathioprine Amidophosphoribosyltransferase inhibitor | PPAT | Phase 3 | Central Nervous System Inflammation | Dec 2026 |
| Assistance Publique - Hôpitaux de Paris | Azathioprine Amidophosphoribosyltransferase inhibitor | PPAT | Phase 3 | Acute Demyelinating Syndrome | Apr 2027 |
| University of Nebraska | Azathioprine Amidophosphoribosyltransferase inhibitor | PPAT | Phase 3 | Rheumatoid Arthritis | Mar 2028 |
| University of Pennsylvania | Azathioprine Amidophosphoribosyltransferase inhibitor | PPAT | Phase 2 | Relapsing Polychondritis; Primary Cutaneous Vasculitis | Jul 2027 |
| University Hospital, Antwerp | Mercaptopurine Amidophosphoribosyltransferase inhibitor | PPAT | Phase 1 | Acute Myeloid Leukemia, in Relapse | Dec 2026 |
| Haukeland University Hospital | Mercaptopurine Amidophosphoribosyltransferase inhibitor | PPAT | Phase 1 | Acute Myeloid Leukemia, Adult | Sep 2029 |
Rheumatoid Arthritis (1) Central Nervous System Inflammation (1) Crohn Disease (1) Myocarditis (1) Relapsing Polychondritis (1) Primary Cutaneous Vasculitis (1) Acute Myeloid Leukemia, in Relapse (1) Acute Demyelinating Syndrome (1) Acute Myeloid Leukemia, Adult (1)
small molecule (5), mixed (2), antibody (1)
University of Nebraska (1) Hospices Civils de Lyon (1) Children's Hospital of Fudan University (1) Medical University of Warsaw (1) University of Pennsylvania (1) University Hospital, Antwerp (1) Assistance Publique - Hôpitaux de Paris (1) Haukeland University Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.